If you are or ever were a fighter pilot …

Apparently the US Air Force (USAF) has become concerned that being a fighter pilot may increase risk for a diagnosis of prostate cancer. For those who are interested, here’s a link to the relevant article on the McClatchy news service. … READ MORE …

Patient-reported outcomes and the management of prostate cancer

Andrew Vickers, PhD, who works at the Memorial Sloan-Kettering Cancer Center in New York, is not a physician. He is a statistician and a research methodologist. And he is a member of the Scientific Advisory Board to The “New” Prostate Cancer InfoLink. … READ MORE …

A chance for US patients to “speak to power”

The roles of patients, patient advocates, and other members of the public in decision-making about the research that is funded by NIH and other agencies here in America is sadly somewhat limited, … READ MORE …

Spontaneous remission in low-risk forms of prostate cancer

The issue of spontaneous remission of low-risk forms of prostate cancer came up yesterday during a meeting of Prostate Cancer International’s Active Surveillance Virtual Support Group (ASVSG). … READ MORE …

Chris Haiman is looking for 10,000 black men (with prostate cancer)!

The RESPOND study, which was initiated in July last year, appears to be the largest-ever study of risk factors for prostate cancer among the African American community, and probably among Black men worldwide. … READ MORE …

No pooping on PCF’s parade, please!

Some 35+ years ago, a guy called Barry Marshall and his colleague Robin Warren discovered that changes to the levels of certain bacteria in the gut led to development of ulcers … and changed everything about the way ulcers are treated. … READ MORE …

UK to invest 75 million in prostate cancer research

According to an announcement on Tuesday from  10 Downing Street in London, Theresa May, the British Prime Minister, has committed to investing £75 million (about US$106 million) in prostate cancer research. … READ MORE …

On active and proactive surveillance

Once upon a time (and not so long ago) newly diagnosed men with some types of prostate cancer used to think your sitemaster was out of his tiny mind when he would suggest to them that they might be wise to just monitor their situation rather than rush into treatment. … READ MORE …

Two leading women talk about the future of treatment of advanced prostate cancer

Nearly 30 years ago, when your sitemaster first attended a prostate cancer meeting (in 1989) related to the upcoming approval of a new drug called flutamide, he doesn’t remember there being a single clinician at the meeting who was female — out of the 150 or so urologists and medical oncologists who had been invited. … READ MORE …

Congress approves $100 million in prostate cancer research funding through DoD

When it passed the Omnibus appropriations bill for the financial year 2018 at the end of last week, Congress increased funding for prostate cancer research from $80 to $100 million through the Department of Defense’s Congressionally Directed Medical Research Program (CDRMP). … READ MORE …

Broad Institute launches the Metastatic Prostate Cancer Project

Last May we had told you about an initiative at the Broad Institute in Cambridge, Massachusetts, designed — initially —  to generate a comprehensive database of advanced prostate cancer treatment results based on the genetics of individual patients and their tumors. … READ MORE …

Sexual function after prostate cancer treatment in the MSM community

There is a significant knowledge gap concerning sexual function for prostate cancer patients in the men who have sex with men (MSM) community, because all of the existing assessment tools are designed for the heterosexual population. … READ MORE …

Chance and progress in the treatment of cancer

Those readers who have limited knowledge of how “translational research” often occurs and progresses (or fails) — particularly in the field of cancer therapy — might like to read this article by Rosenbaum in this week’s issue of The New England Journal of Medicine. … READ MORE …

The evolution of evaluation of risk for clinically significant prostate cancer

Whatever one may happen to think about the value of the PSA test, we all know that it is very bad at actually telling a doctor or a patient if that patient is at real risk for clinically significant prostate cancer. So, from that perspective … READ MORE …

More about screening … current and future issues

So there are two new articles recently published on the prostate cancer screening issue. One deals with the numbers of men  in America who seem to be getting screened today. The other addresses whether there should be different guidance on prostate cancer screening for African Americans as opposed to “the rest of us” (Caucasians, Hispanics, and “white” Americans). … READ MORE …